These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21481708)

  • 1. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.
    Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O'Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK
    Lancet; 2011 Apr; 377(9773):1256-63. PubMed ID: 21481708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
    Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
    EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
    Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
    Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
    Pass RF
    J Clin Virol; 2009 Dec; 46 Suppl 4(Suppl 4):S73-6. PubMed ID: 19647480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
    Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
    J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
    J Infect Dis; 2024 Aug; 230(2):455-466. PubMed ID: 38324766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine prevention of maternal cytomegalovirus infection.
    Pass RF; Zhang C; Evans A; Simpson T; Andrews W; Huang ML; Corey L; Hill J; Davis E; Flanigan C; Cloud G
    N Engl J Med; 2009 Mar; 360(12):1191-9. PubMed ID: 19297572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
    Nakamura R; La Rosa C; Longmate J; Drake J; Slape C; Zhou Q; Lampa MG; O'Donnell M; Cai JL; Farol L; Salhotra A; Snyder DS; Aldoss I; Forman SJ; Miller JS; Zaia JA; Diamond DJ
    Lancet Haematol; 2016 Feb; 3(2):e87-98. PubMed ID: 26853648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for cytomegalovirus.
    Bernstein DI
    Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
    Marshall BC; Adler SP
    Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial.
    Aldoss I; La Rosa C; Baden LR; Longmate J; Ariza-Heredia EJ; Rida WN; Lingaraju CR; Zhou Q; Martinez J; Kaltcheva T; Dagis A; Hardwick N; Issa NC; Farol L; Nademanee A; Al Malki MM; Forman S; Nakamura R; Diamond DJ;
    Ann Intern Med; 2020 Mar; 172(5):306-316. PubMed ID: 32040960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.